Having spent six years developing processes for evaluating treatments for rare diseases, leading the Highly Specialised Technologies (HST) programme at NICE and developing Health Technology Assessments with the Advisory Group for National Specialised Commissioning, I am all too familiar with the challenges in assessing high-cost, low-volume treatments.
Among academics, the maxim “publish or perish” means publish your research, or risk losing your job. The term could equally apply to business, where the future winners are the companies who seize the opportunity to tell their own story, and reach audiences directly. A seismic shift is taking place, driven by the proliferation of social media and a breakdown in traditional publishing models.
Measurement and evaluation